Comparative Pharmacology
Head-to-head clinical analysis: BENSULFOID versus SILVADENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENSULFOID versus SILVADENE.
BENSULFOID vs SILVADENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; may inhibit Na+/K+-ATPase pump and increase renal sodium excretion
Silver sulfadiazine exerts bactericidal activity by releasing silver ions that bind to microbial DNA and proteins, inhibiting cell wall synthesis and cell division. The sulfadiazine component provides additional bacteriostatic action by competing with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase in folic acid synthesis.
Bensulfoid: not a recognized drug. No data available.
Apply a thin layer (approximately 1/16 inch) of 1% cream to the affected area once or twice daily. Use a sterile gloved hand. Reapply as needed to maintain coverage.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours in adults with normal renal function; prolonged to 24-48 hours in moderate renal impairment (CrCl 30-50 mL/min).
The terminal elimination half-life of sulfadiazine is approximately 10-12 hours in patients with normal renal function. Silver has a very long biological half-life (weeks to months) due to tissue deposition.
Renal excretion of unchanged drug: 70-80%; biliary/fecal: 15-20%; metabolic inactivation accounts for the remainder.
Silver sulfadiazine applied topically results in minimal systemic absorption. The sulfadiazine component is primarily excreted renally (approximately 70% as unchanged drug and metabolites), with biliary/fecal excretion accounting for a small fraction (<10%). Silver is largely retained in tissues, not excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic